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Abstract
PURPOSE: The aim of this study was to evaluate the re-
lationships among [18F]fluorodeoxyglucose ([18F]-FDG)
uptake, Glut-1 and HK-II expressions, and grade of in-
flammation in resected lung lesions. MATERIALS AND
METHODS: Sixty patients had undergone preopera-
tive 18F-FDG-PET imaging and thoracotomy. For semi-
quantitative analysis of 18F-FDG uptake, partial volume
effect corrected maximum standardized uptake values
(pSUVs) were calculated. Immunohistochemical stain-
ing was performed in resected specimens using anti–
Glut-1, anti–HK-II, and anti–proliferative cellular nuclear
antigen (PCNA) antibodies, and immunoreactivities
were scored as G-, H-, and P-indexes on a five-point
scale (0: 0%; 1: ˜20%, 2: ˜40%; 3: ˜60%; 4: ˜80%, and
5:˜100% percentages of strongly immunoreactive cells).
Grade of inflammation was also evaluated. RESULTS:
The malignant lesions had higher pSUV and higher
G- and H-indexes than nonmalignant lesions. pSUVs
correlated with the G- (p < .001), H- (p < .01), and
P-indexes (p < 0.01) in malignant lesions. In adeno-
carcinomas, cancers with lower differentiation showed
higher expression of Glut-1 and HK-II than those with
higher differentiation. A positive linear regression was
observed between pSUVs and the grading of inflam-
mation in nonmalignant lesions (p < 0.05). CONCLU-
SIONS: Our study indicates that 18F-FDG uptake in lung
cancer correlates well with Glut-1, HK-II, and PCNA
expression. For nonmalignant lesions, the presence
of a higher inflammatory process correlated with
18F-FDG uptake.
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Introduction
Lung cancer is the most common cause of cancer death in
the United States and Japan [1,2]. In Japan, lung cancer
was responsible for 22.0% of deaths in men and 12.7% in
women, being characterized as the first and second most
common cause of death, respectively [2].
It has long been recognized that cancer cells have increased
rates of glucose metabolism compared to healthy cells [3,4]. A
variety of mechanisms have been proposed for the accelerated
glucose use seen in growing tumors and in transformed and
malignant cells [5]. Transmembrane transport mediated by
specific transporters [6] is considered to be one of the most
important mechanisms for enhancing glucose influx into cells.
Furthermore, increased concentrations of hexokinase [7,8] with
decreased rates of glucose-6-phosphatase [9] have been
reported to accelerate glucose phosphorylation, which results
in increased glucose consumption. Among several subtypes,
glucose transporter protein, type 1 (Glut-1) and glucose phos-
phorylation enzyme type II (Hexokinase II, or HK-II) are known
to be the most important subtypes for glucose metabolism in
cancer cells [10–14].
Positron emission tomography (PET) imaging with
[18F]fluorodeoxyglucose ([18F]FDG) has become an important
nonlinvasive technique for the evaluation of solitary pulmo-
nary nodules, cancer staging, detection of recurrent neo-
plasms, and radiotherapy planning [15–21]. The rationale
for the use of [18F]FDG is based on the increase glucose
metabolism of malignant cells, in which [18F]FDG, an ana-
logue of glucose, is absorbed, phosphorylated, and trapped
in the cytosol of the cells. However, the exact mechanism
of [18F]FDG accumulation in malignant lesions has not been
fully elucidated.
In addition, [18F]FDG uptake is not specific for malignancy;
some benign abnormalities can demonstrate increased tracer
activity as well [22]. Some studies showed low specificity of the
diagnostic value of [18F]FDG-PET in differentiation between
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cancer and benign diseases. These studies have addressed
the problem of differentiation between malignant lesions
and granulomatous infections, including pulmonary tuber-
culosis (TB) and histoplasmosis [22–25].
In the present study, we examined the immunohisto-
chemical expressions of Glut-1, HK-II, and the proliferative
marker (proliferative cellular nuclear antigen, or PCNA) in
pulmonary lesions (malignant and nonmalignant) to eluci-
date the mechanism of [18F]FDG accumulation. We also
evaluated potential differences in the expression pattern of
these three antigens among various histologic types and
compared the results with clinical data.
Materials and Methods
Subjects of the Study
In this prospective study, 60 patients (38 men, 22 women;
age range, 26–79 years old; mean age, 65.0 ± 11.5 years
old) with 41 primary lung cancers, 5 pulmonary metastatic
lesions, and 14 nonmalignant lesions who had undergone
both preoperative [18F]FDG-PET imaging and thoracotomy
were enrolled in this study. All patients underwent thora-
cotomy within 4 weeks after their [18F]FDG-PET study. Final
diagnoses and sizes of the primary tumors were confirmed
histopathologically in resected specimens obtained by tho-
racotomy in all patients. None of them received any previous
chemotherapeutic or radiotherapeutic treatments. None of
the patients had diabetes, and the serum glucose level
just before [18F]FDG injection was less than 120 mg/dl in
all patients. Before being enrolled in this study, each patient
gave written informed consent, as required by the Kyoto
University Human Study Committee.
PET Study
18F was produced by a 20Ne (d, alpha) 18F nuclear re-
action, and [18F]FDG was synthesized by the nucleophilic
substitution method using an [18F]FDG-synthesizing instru-
ment F-100 (Sumitomo Heavy Industries, Co. Ltd., Tokyo,
Japan) and a cyclotron, CYPRIS-325R (Sumitomo Heavy
Industries, Co. Ltd.) [26,27]. All patients were examined
with a high-resolution, whole-body PET scanner with an
18-ring detector arrangement (Advance; General Electric
Medical systems, Milwaukee, WI).
The patients fasted for more than 4 hours before the
injection of [18F]FDG. All subjects received an intravenous
injection of [18F]FDG (296 ± 74 MBq), and the acquisition
of whole-body PET images started 50 minutes later. The
patient laid supine on the PET table with the arms positioned
on the sides. The patient was then fixed in place by wrap-
ping a holding belt around the abdomen. Data acquisition
(emission and transmission scan) was performed in two-
dimensional imaging mode with septae in place. Emission
images were acquired for 3 minutes per bed position, and
each postemission transmission scan was obtained for
1 minute per position. Whole-body scan (from face to upper
thigh) was performed in each patient using five or six bed
positions according to the height of each patient. The data
were reconstructed using the ordered subsets expectation
maximization method (OSEM) using 16 subsets, 3 iterations,
and 128  128 array size.
Image Analysis
PET images were interpreted by at least three experi-
enced nuclear medicine physicians with all available clini-
cal information and correlative conventional imaging as
anatomic guidance. For semiquantitative analysis of the
[18F]FDG uptake, regions of interest (ROI) were manually
defined on transaxial tomograms. ROI were placed on the
lesions using a semiautomated method that encompassed
all pixels that had uptake values of greater than 90% of
the maximum uptake in that slice. In patients for whom no
nodules were detectable by PET, the ROI was drawn based
on the chest CT scans. The maximum standardized uptake
value (SUV) was used for the quantitative analysis of tumor
[18F]FDG uptake:
SUV ¼ C ðkBq=mlÞ
ID ðkBqÞ=body weight ðkgÞ ð1Þ
where C represents tissue activity concentration measured
by PET, and ID represents the injected dose. By using the
average diameter of the resected tumor, the SUV data were
corrected for partial volume effects (PVE) in lesions with
diameter <2.8 cm, based on recovery coefficient (RC) curve.
RCwas calculated in our institution using spherical phantoms
based on the method of Akashi et al. [28] (data not shown).
EachRCbased on theRC curvewas applied to the correction




¼ BG SUVþ ðmeasured SUV BG SUVÞ
RC
ð2Þ
BG SUV was defined as average SUV on a 10 
10-pixel ROI adjacent to the tumor. This ROI was placed
either medial or lateral to the tumor to minimize antero-
posterior background variations, and away from the chest
wall and mediastinum [30]. A lesion with SUV or partial
volume effect corrected maximum standardized uptake
value (pSUV) higher than 2.5 was considered positive
for malignancy.
Histologic Examination
All the patients underwent surgical resection of the lung
nodule. Paraffin-embedded specimens were processed for
anti–Glut-1, anti–HK-II, or anti–PCNA immunostaining or
routine hematoxylin–eosin staining. The polyclonal rabbit
anti –glucose transporter antibody reactive with human
Glut-1 (brain/erythrocyte type) and the monoclonal mouse
antiproliferating cell nuclear antigen (PCNA) antibody
reactive with proliferating human cells were purchased
from DAKO (Carpinteria, CA). Both antibodies were diluted
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1:200 with 0.05 mol/l Tris–HCl buffer containing a carrier
protein and 0.015 mol/l sodium azide. The polyclonal rabbit
anti-hexokinase antibody reactive with rat HK-II iso-
enzyme was purchased from Chemicon International, Inc.
(Temecula, CA). It was diluted 1:500 with 0.05 mol/l Tris–
HCl buffer containing a carrier protein and 0.015 mol/l
sodium azide.
Paraffin was removed from sections of each tumor using
xylene (3  5 minutes) and ethanol in various dilutions.
Before immunohistochemical procedures, unmasking treat-
ments were performed on all sections, following previous
established procedure [30]. Sections for anti–Glut-1 immu-
nostaining were incubated with target retrieval solution
(TRS; DAKO), using the hot bath methods at 95jC to 99jC
for 20 minutes. The other sections, including those for anti–
HK-II and anti-PCNA immunostaining, were unmasked by
the microwave method using a distilled water bath for
15 minutes.
After 20 minutes of cooling, the sections were washed
with phosphate-buffered saline (PBS), containing 20 mmol/l
sodium phosphate and 150 mmol/l NaCl (pH 7.0), for
15minutes. Then, the endogenous peroxidase activities were
blocked for 10 minutes at room temperature (RT) with 0.3%
hydrogen peroxide in distilled water, and were washed
with PBS for 5 minutes. Nonspecific binding was blocked
for 30 minutes at RT with a blocking buffer solution (DAKO),
which contained 10% normal bovine serum in PBS. In the
next step, each section was incubated with the anti-PCNA,
anti–Glut-1, or anti–HK-II antibodies as a primary antibody
for 1 hour at RT. Parallel sectionswere incubatedwith healthy
rabbit IgG (20 mg/ml) as negative controls.
Then, all the sections were washed with PBS with 0.05%
polyoxyethylene sorbitan monolaurate (Tween 20; Kanto
Chemical Co., Tokyo, Japan) for 15 minutes. In the fol-
lowing steps, each section was stained by the horseradish
peroxidase (HRP)– labeled polymer method, using an Envi-
sion Kit/HRP 3,3V-diaminobenzidine tetrahydrochloride
(DAB; DAKO). For linking, the sections were incubated
with the labeled polymer for 60 minutes at RT and washed
with PBS with 0.05% Tween 20 for 15 minutes. As a
substrate–chromogen solution, DAB was used at RT for
10 minutes, and diluted at 1 mg/ml with 0.05 mol/l Tris–HCl
buffer, pH 7.5. All sections were then rinsed gently and
washed with distilled water for 5 minutes. In the final step,
the sections were lightly counterstained with Mayer’s he-
matoxylin for 4 minutes, and then washed in a running wa-
ter bath. The sections were then dehydrated twice by
ethanol bath for 2 minutes and then dried. A coverslip was
positioned with mounting media. All slides were examined
by light microscopy.
Microscopic Analysis
Forty-one primary malignant lesions, 5 metastatic speci-
mens, and 14 nonmalignant specimens were available for
pathologic evaluation. A well-experienced pathologist in
lung diseases (M.K.) reviewed all of the pathologic mate-
rials. In those cases of neoplastic lesions, tumor type [ade-
nocarcinoma (AC), squamous cell carcinoma (SCC), etc.],
tumor subtype (papillary, acinar, tubular, and mucinous),
differentiation (poorly, moderately, or well differentiated),
surgico-pathologic stage, and inflammatory changes were
evaluated on each specimen. For those specimens of
non-neoplastic lesions, the main diagnosis (e.g., tubercu-
losis, obstructive pneumonia), inflammatory changes, and/
or fibrotic changes were carefully evaluated. In terms of in-
flammatory changes, a specific grading was performed on
a four-point scale for all specimens (malignant and non-
malignant) based on the infiltrative inflammatory cells pre-
sented in the specimen as follows: 0—negative, 1—mild,
2—moderated, and 3—marked. This analysis was per-
formed twice and averaged for further comparisons with-
out significant variability.
Immunohistochemical analyses for anti–Glut-1 and anti–
HK-II antibodies were independently performed twice by
three well-experienced physicians who were unaware of
the pSUVs. In each analysis, the percentages of strongly
immunoreactive tumor cells in the total tumor cells was
visually analyzed in several low-power fields (original mag-
nification, 10  10) covering the entire specimen, and the
average percentage was calculated and scored on a five-
point scale (0: 0%; 1: 1–20%; 2: 21–40%; 3: 41–60%; 4:
61–80%; 5: 81–100%) for each counting trial. Then, scores
from two counting trials were averaged again to give the
Glut-1 expression index (G-index) or HK-II expression index
(H-index).
To count PCNA-positive tumor cells, we followed the
method described by Higashi et al. [32]. First, the sections
were scanned in low-power fields to determine representa-
tive areas. High-power fields ( 20) were used for counting.
Each analysis was performed in a minimum of 10 high-power
fields with a total of two analyses per physician. All nuclei
that showed a brown stain were considered to be positive.
The proliferative fraction of tumor cells was counted by the
percentage of PCNA-positive cells (PCNA-positive cells/
total tumor cells). Furthermore, the average percentage
was calculated and scored on a five-point scale in the same
manner performed for Glut-1 and HK-II for each counting
trial. Then all scores from two counting trials per each phy-
sician were averaged again to give the PCNA expression
index (P-index).
As for nonmalignant lesions, immunohistochemical analy-
ses for anti–Glut-1, anti–HK-II, and anti-PCNA antibodies
were performed in the same manner described above. How-
ever, the percentage of strongly immunoreactive nontumor
cells was compared to the total nontumor cells analyzed in
several low-power fields (original magnification, 10  10)
covering the entire specimen. The average percentage was
calculated and scored on a five-point scale (as described
above for malignant lesions).
Statistical Analysis
Data are expressed as mean ± standard deviation (SD).
Simple comparisons using Student’s t test were applied
to compare two groups of different pathologies, whereas a
multiple comparison (one-way ANOVA) was also applied
between several groups of histologic diagnoses. Analyses
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of correlation were carried out using a Spearman rank test,
as well as linear regression analyses. All statistical analyses
were performed using SPSS version 9.0. Values were con-
sidered significant at P < .05.
Results
Histologic Findings
Table 1 summarizes the characteristics of patients with
malignant lesions in this study. Among the 41 primary pul-
monary malignant lesions, 32 were diagnosed as AC
(78.1%), six were diagnosed as SCC (14.6%), and the
remaining three lesions (7.3%) were diagnosed as other
primary lung tumors. Most of the patients (80.5%) had an
early stage of disease (stages I and II). Five lesions were
diagnosed as metastatic lesions. Maximal tumor diameters,
estimated from histopathologic specimen, ranged from 0.6
to 7.8 cm. The SCCs showed larger diameters than ACs,
but not statistically significant. No significant correlations
were observed among size of nodules, stage of disease,
and differentiation of the tumor.
Table 2 summarizes the characteristics of patients with
nonmalignant lesions. Ten lesions (71.4%) were considered
as TB. Maximal tumor diameters ranged from 1.0 to 4.3 cm.
The sizes of nonmalignant lesions were relatively smaller
than those observed for malignant lesions (NS).
[18F]FDG PET Findings
Using a cutoff value of 2.5 for SUV, [18F]FDG PET cor-
rectly diagnosed 40 of 46 malignant lesions (sensitivity =
87.0%). Once the PVE correction was considered in lesions
smaller than 2.8 cm, the sensitivity of [18F]FDG-PET diag-
nosis increased up to 97.8%, with 45 true-positive cases
(using a cutoff value of 2.5 for pSUV).
In the present study, [18F]FDG PET demonstrated low
specificity in the differentiation between malignant and
Table 1. Patient Characteristics (Malignant Lesions).
Diagnosis Type Size (mm) SUV pSUV











21.1± 9.1 5.8 ± 3.7 7.7 ± 4.2
Solid growth
(n = 2)




Total 23.2 ± 10.5 7.3 ± 5.8 9.0 ± 6.3
SCC (n = 6) – 32.7 ± 16.0 15.2 ± 4.7 19.5 ± 7.5
Neuroendocrine Epithelial 6 3.5 11.8
Thymoma Large cell 78 6.6 6.6
Pleomorphic
carc
Lymphocyte 50 23.3 23.3
Metastatic (n = 5)
Adenocarcinoma Acinar 17 12.4 19.0
SCC – 25 16.4 16.1
Renal Ca Clear cell 15 4.5 7.9
Esophageal Ca – 10 2.3 6.5
PNET Skin tumor 70 4.0 4.0
Total (n = 46) 26.3 ± 15.8 8.7 ± 6.4 10.9 ± 7.3
SUV = nonpartial volume effect corrected maxSUV; pSUV = partial volume
effect corrected maxSUV; SCC = squamous cell carcinoma of the lung;
pleomorphic carc = pleomorphic carcinoma; Ca = cancer; PNET = primary
neuroendocrine tumor; acinar/pap = acinar and papillary type.
Table 2. Patient Characteristics and Results of Immunohistochemistry (Nonmalignant Lesions).




Tuberculosis 12 1.5 2.4 0 1 2 1 Necrosis (+)
Tuberculosis 15 4.1 6.9 0 2 3 1 Multiple granulomas
Tuberculosis 30 6.2 6.2 0 0 2 2 Necrosis (+), PCNA (+) in epithelial cells
Tuberculosis 30 22.4 22.4 0 2 1 3 Organizing pneumonia
Tuberculosis 43 4.5 4.5 0 3 1 1 Necrosis (+), fibrosis (+)
Tuberculosis 33 12.2 12.2 0 2 0 2 PCNA (+) in epithelial cells
Tuberculosis 25 3.2 3.3 0 1 2 1 Necrosis (+), calcification (+), fibrosis (+)
Tuberculosis 20 4.1 5 0 2 1 2* Necrosis (+), calcification (+), fibrosis (+),
chronic inflammation pattern
Tuberculosis 10 1.8 4.6 0 1 2 1
Tuberculosis 10 5.7 20.1 0 1 2 3 Intra–air space granulomatous (+)
Total (TB) 22.8 ± 11.2 6.6 ± 6.3 8.8 ± 7.1 0 1.5 ± 0.8 1.6 ± 0.8 1.7 ± 0.9
Chronic
inflammation
18 2.4 3.3 0 0 0 3* Chronic inflammation pattern, fibrosis (+),
PCNA (+) in germinal center hyperplasia
Organizing
pneumonia
20 5.2 6.5 0 0 0 3* Chronic inflammation pattern, UIP pattern, fibrosis
and smooth muscle cell proliferation (+), HK-II
(+) in smooth muscle cell
Pulmonary
sequestration
10 3.3 10.7 0 0 0 3 Pneumonia and bronchiolitis, chronic inflammation;
smooth muscle cell proliferation (+); germinal
center hyperplasia, HK-II (+) in smooth muscle cell
Paucilocalized
fibrosis
10 1.7 3.3 0 0 0 1 Smooth muscle cell proliferation (+), fibrosis (+)
Total (non-TB) 14.5 ± 5.3 3.2 ± 1.5 6.0 ± 3.5 0 0 0 2.0 ± 1.4
Total 20.4 ± 10.4 5.6 ± 5.5 8.0 ± 6.3 0 1.1 ± 1.0 1.1 ± 1.0 1.9 ± 0.8
SUV = nonpartial volume effect corrected maxSUV; pSUV = partial volume effect corrected maxSUV; Grade of Inflam = grade of inflammatory process in the
specimen; UIP = usual interstitial pneumonia; P = P-index; G = G-index; H = H-index; total (TB) = averaged values from pulmonary tuberculosis; total (non-TB) =
averaged values from nonpulmonary tuberculosis.
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nonmalignant lesions. Without PVE correction, the speci-
ficity was 21.4% with 11 false-positive cases, whereas
specificity was 14.3% with 13 false-positive cases by the
use of PVE correction. Therefore, the accuracy showed
similar results in diagnoses using SUV and pSUV (76.7%
and 78.3%, respectively).
The pSUVs were higher for malignant lesions (10.9 ± 7.3)
than those for nonmalignant lesions (8.0 ± 6.3), although this
difference was not significant (Figure 1A). Among all pulmo-
nary nodules evaluated in this study, the SCC showed the
highest pSUV (19.5 ± 7.5) (ANOVA, P < .01). The pSUVs
for AC (9.0 ± 6.3) were higher than that for nonmalignant
lesions; however, this difference was not statistically signifi-
cant (Figure 1B). pSUV did not show any correlation with
stages of disease and sizes of tumor.
Immunohistochemical Findings
Tables 2–4 summarize the findings of the immuno-
histochemical analyses using anti–Glut-1, anti–HK-II, and
anti-PCNA antibodies (G-index, H-index, and P-index,
respectively). The scores for each index varied between
three observers; however, the interobserver and intraob-
server variabilities were less than one point in each case
and were considered negligible in this study.
Primary non small cell lung cancer (NSCLC) Immuno-
reactivity of Glut-1 was mainly observed in the membrane of
cancer cells; however, Glut-1 granules were also present in
the cell cytoplasm (Figure 2, A and B). Positive cytoplasmic
granules were observed more frequently in ACs than in
SCCs. The expression of Glut-1 was often observed in cancer
cells around necrotic sites (data not shown). No staining was
observed in the section of negative controls (data not shown).
All SCC tissues were Glut-1–positive (Table 3). The aver-
age intensity of staining was significantly higher in SCCs
(4.5 ± 0.7) than that for ACs (0.9 ± 1.4) (P < .001). As for
ACs, the average intensity of Glut-1 staining was variable
according to tumor differentiation (Table 4). However, all
cases of well-differentiated AC were negative for Glut-1. The
Glut-1 expression showed a close positive relationship with
pSUV (r = 0.66, P < .001; Figure 3A) for malignant lesions.
Table 3. Results of Immunohistochemistry and Diagnostic Imaging (Malig-
nant and Nonmalignant Lesions).








7/14 0/14 8/14 13/14
Moderately
differentiated (n = 13)
8/13 7/13 11/13 13/13
Poorly differentiated
(n = 5)
4/5 4/5 5/5 5/5




1/1 1/1 1/1 1/1
Moderately
differentiated (n = 5)
5/5 5/5 5/5 5/5






1/1 0/1 1/1 1/1
Pleomorphic carc
(poorly differentiated)
1/1 1/1 0/1 1/1
1/1
Metastatic lesions
SCC 1/1 1/1 1/1 1/1
Adenocarcinoma 1/1 1/1 1/1 1/1
Renal cell carcinoma 1/1 1/1 1/1 1/1
Esophageal cancer 0/1 0/1 0/1 1/1
PNET 1/1 0/1 1/1 1/1
Total 31/46 21/46 34/46 45/46
Nonmalignant lesions
Tuberculosis 0/10 9/10 9/10 9/10
Nontuberculosis 0/4 0/4 0/4 4/4
Total 0/14 9/14 9/14 13/14
Immunohistochemistry (+) = positive cases of PCNA, Glut-I, and HK-II expres-
sions (grades 1–5); [18F]FDG-PET (+) (pSUV > 2.5) = positive cases of
[18F]FDG-PET (+) by using a cutoff of 2.5; Percentage = percentagemean value
ofPCNA,Glut-1, andHK-II expressions;PNET=primaryneuroendocrine tumor.
Figure 1. pSUV values plotted with respect to tumor histologic diagnosis. (A) The pSUVs were higher for malignant lesions (mean ± SD, 10.9 ± 7.3) than that
for nonmalignant lesions (8.0 ± 6.3) (NS). (B) The SCC showed the highest pSUV (mean ± SD, 19.5 ± 7.50) (ANOVA, P < 0.01). The AC lesions had higher pSUVs
than that for nonmalignant lesions (NS). AC, adenocarcinoma of the lung; SCC, squamous cell carcinoma of the lung.
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A very fine uniform granular pattern was observed in the
cytoplasm of most HK-II–positive cancer cells (Figure 2D). A
similar result has been previously described by Brown et al.
[33]. Smooth muscle cells and some macrophages in the
airway showed HK-II–positive staining (Figure 4). All SCC
tissues studied were HK-II–positive, as well as the poorly
differentiated ACs (Table 3). The expression of HK-II in
SCCs was higher (2.4 ± 1.7) than that for ACs (1.8 ± 1.5)
(Table 4); however, this finding was not statistically signifi-
cant. The HK-II expression showed a positive relationship
with pSUV (r = 0.43, P < .01; Figure 3B). In well-differentiated
ACs, all of them were negative for Glut-1, whereas 57.1%
was positive for HK-II.
The PCNA expression was positive in all SCCs (Table 3)
with a high intensity of PCNA-positive nuclei (2.6 ± 1.4)
(Table 4). The number of PCNA-positive nuclei in ACs
(1.3 ± 1.3) showed a smaller average value with wide devia-
tion, compared to that in SCCs (NS). Table 3 summarizes
the immunohistochemical findings for PCNA in malignant
lesions. The P-index showed a significant correlation with
pSUV (r = 0.42, P < .01; Figure 3C). In addition, the PCNA
expression showed a closed positive correlation with Glut-1
or HK-II expression (r = 0.58, P < .01 and r = 0.52, P < .01;
respectively) (Figure 5, A and B).
Concerning tumor differentiation of ACs (well, moderately,
and poorly differentiated types), the poorly differentiated type
showed the highest values of pSUV and G-index (ANOVA,
P < .05 and P < .001, respectively). A linear regression
analysis showed a significant correlation between G-index
and tumor differentiation (r 2 = 0.45, P < .001; Figure 6).
A significant relationship was also observed between
H-index or pSUV and tumor differentiation (r 2 = 0.14, P < .05
and r 2 = 0.26, P < .01, respectively).
In some cases of primary NSCLC lesions, the inflamma-
tory process was recognized both in the inside of the tumor
tissues and in the surrounding interstitial spaces. The inten-
sity was variable between specimens (0.8 ± 1.0) (Table 4),
and no significant correlation was observed with G-index,
H-index, or pSUV.
Other malignant lesions. The neuroendocrine tumor
showed negative staining for all antibodies applied, whereas
the thymoma and undifferentiated tumor had variable weak
positive staining for Glut-1 or HK-II (Tables 3 and 4). Two of
five metastatic lesions in the lung (SCC and AC) were
diagnosed as pulmonary metastatic lesions from the primary
site in the lung. The metastatic SCC had a high expression
of all antibodies. Unexpectedly, the metastatic AC (well-
differentiated type) showed a positive staining for anti–
Glut-1 and HK-II. The other three nonpulmonary metastatic
lesions showed variable staining (Tables 3 and 4).
Nonmalignant lesions. In TB, the Glut-1–positive staining
was often localized in the membranes of granulocytes and
macrophages around the necrotizing granulomas, as well as
in the cytoplasm (Figure 2C). For the HK-II–positive staining,
a uniform granular pattern of staining was also observed in
the cytoplasm of granulocytes and macrophages in a similar
manner described for Glut-1 (Figure 2F).
The Glut-1–positive staining was observed in 9 of
10 cases of TB (1.5 ± 0.8), whereas all non-TB lesions were
Glut-1–negative stainings (Table 2). The HK-II–positive
staining was also observed in 9 of 10 cases of TB (1.6 ± 0.8),
with negative staining in non-TB lesions aswell (Table 2). The
G-index and H-index in nonmalignant lesions were smaller
compared to that in malignant lesions (NS). The G-index
and H-index did not show any significant correlation with
pSUV for nonmalignant lesions. No staining was observed
for PCNA antibody in all nonmalignant tissues.
In all cases of nonmalignant lesions, the inflammatory
process was well recognized (Table 2). A chronic inflamma-
tory process was observed in 2 of 10 patients with TB,
Table 4. Results of Immunohistochemistry (Malignant Lesions).
Diagnosis Differentiation Indexes Grade of Inflam Percentage (%)
P G H PCNA Glut-1 HK-II
Primary (n = 41)
Adenocarcinoma (n = 32) Well-differentiated (n = 14) 1.1 ± 1.4 0 1.4 ± 1.7 0.6 ± 0.9 18.4 ± 26.1 0 26.6 ± 33.4
Moderately differentiated (n = 13) 1.4 ± 1.4 1.0 ± 1.2 1.8 ± 1.3 0.7 ± 0.9 25.0 ± 27.0 17.8 ± 23.3 32.2 ± 25.2
Poorly differentiated (n = 5) 2.0 ± 1.4 2.8 ± 1.9 3.0 ± 1.6 1.6 ± 1.1 38.6 ± 25.9 54.6 ± 37.5 58.6 ± 30.7
Total 1.3 ± 1.3 0.9 ± 1.4 1.8 ± 1.5 0.8 ± 1.0 24.3 ± 26.5 15.8 ± 27.4 34.0 ± 31.0
SCC (n = 6) Well-differentiated (n = 1) 3 4 5 3 60 80 100
Moderately differentiated (n = 5) 2.4 ± 1.7 4.4 ± 0.9 2.2 ± 1.9 1.0 ± 1.4 48.0 ± 33.5 88.0 ± 17.9 41.2 ± 38.1
Total 2.6 ± 1.4 4.5 ± 0.7 2.4 ± 1.7 0.8 ± 1.3 48.8 ± 30.0 88.9 ± 16.1 46.7 ± 36.5
Neuroendocrine – 0 0 0 0 0 0 0
Thymoma – 2 0 1 3 33 0 20
Pleomorphic carc Poorly differentiated 1 2 0 1 20 33 0
Metastatic (n = 5)
Adenocarcinoma Well-differentiated 4 2 5 0 73 40 100
SCC Moderately differentiated 5 3 4 0 100 60 73
Renal Ca Poorly differentiated 2 1 5 1 40 20 100
Esophageal Ca Well-differentiated 0 0 0 1 0 0 0
PNET – 1 0 1 0 20 0 13
Total (n = 46) 1.6 ± 1.5 1.3 ± 1.8 1.9 ± 1.7 0.8 ± 1.0 29.5 ± 29.2 25.9 ± 35.2 36.3 ± 33.8
Grade of Inflam = grade of inflammatory process in the specimen; Percentage = average percentage of anti-PCNA, anti –Glut-1, anti –HK-II antibody expression;
P = P-index; G = G-index; H = H-index; SCC = squamous cell carcinoma; Ca = cancer; PNET = primary neuroendocrine tumor.
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whereas a similar pattern was observed in half of the non-
infectious specimens. The necrotic areas were frequently
observed in tuberculosis patients, whereas fibrosis did not
show any specific preferential lesion. The inflammatory pro-
cess was significantly higher in nonmalignant lesions (1.93 ±
0.92) compared to malignant lesions (0.8 ± 1.0) (P < .001).
Figure 3. Comparative analyses between grades of Glut-1 ( G-index), HK-II (H-index), or PCNA ( P-index) expressions with pSUV values in pulmonary malignant
lesions. (A) The G-index showed a significant positive relationship with pSUV (r = 0.66, P < .001). (B) The H-index showed a significant positive relationship with
pSUV (r = 0.43, P < .01). (C) The P-index showed a significant positive relationship with pSUV (r = 042, P < .01).
Figure 2. Immunohistochemical findings and [18F]FDG-PET examinations from selected patients enrolled in the present study. (A, D, and G) Glut-1 expression,
HK-II expression, and [18F]FDG-PET examination from the same patient (patient 33) with well-differentiated SCC, respectively. The highest expression of Glut-1
was observed in the membranes of cancer cells (grade 5) (original magnification, 10), whereas the expression of HK-II was observed throughout the cytoplasm
as small punctuate areas (grade 4) (original magnification, 10). The [18F]FDG-PET examination showed a high [18F]FDG uptake in the posterior lower lobe of the
right lung (panel G; arrow) on the transaxial slice (pSUV = 14.1). (B, E, and H) Glut-1 expression and two representative [18F]FDG-PET reconstructed slices
(coronal and transaxial slices, respectively) from a patient (patient 21) with AC (papillary type, moderate differentiated), respectively. The expression of Glut-1 can
be observed in the membranes of cancer cells and as granules throughout the cell cytoplasm (grade 5) (original magnification, 10). The [18F]FDG PET
examination showed a high uptake in the left lung (panel H; arrow) (pSUV = 12.4). (C, F, and I) Glut-1 expression, HK-II expression, and [18F]FDG PET
examination from a patient with pulmonary tuberculosis (patient 48), respectively. The expression of Glut-1 can be observed in the membranes of cells in the center
of the pulmonary granuloma (grade 2) (original magnification, 4), whereas the expression of HK-II can be observed in areas surround caseating granulomas
throughout the cytoplasm (grade 3) (original magnification, 4). The [18F]FDG-PET examination showed a moderate [18F]FDG uptake in the upper lobe of the left
lung (panel I; arrow) on the transaxial slice (pSUV = 6.9).
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A close positive relationship was observed between the
grading of inflammatory process and the pSUV (r = 0.61,
P < .05; Figure 7) in nonmalignant lesions.
Discussion
[18F]FDG-PET has been described as a useful method for
differentiation between benign and malignant pulmonary
lesions [15,19,20]. [18F]FDG-PET has also been proved to
be useful in the staging of known lung cancer [16,17]. In
addition, [18F]FDG-PET has become important in evaluating
response to radiotherapy and/or chemoradiotherapy for
NSCLC [21]. In a meta-analysis study evaluating 1474 focal
pulmonary lesions of any size, Gould et al. [19] indicated
that the sensitivity of [18F]FDG-PET in detecting malignant
lesions was between 83% and 100% (mean 96%), whereas
specificity was extremely variable.
In the present study, the SUV values (non-PVE corrected)
showed a high sensitivity of [18F]FDG-PET to detect malig-
nant lesions (87%), which is compatible with previous pub-
lished data [15,19,20]. In order to increase the sensitivity
of [18F]FDG-PET in lung cancer, the correction of partial
volume effect was carried out. The sensitivity increased up to
97.8%, once the partial volume effect was corrected (pSUV)
using the RC for lesions smaller than 2.8 cm. This correction
Figure 4. Immunohistochemical findings from a selected patient (patient 20).
In the present study, the HK-II expression in smooth muscle cells was often
observed (arrow).
Figure 5. A comparative analyses between grades of Glut-1 ( G-index) or HK-II (H-index) expressions, with grade of PCNA ( P-index) expressions in pulmonary
malignant lesions. (A) The G-index and P-index showed a significant positive relationship (r = 0.58, P < .01). (B) The H-index and P-index showed a significant
positive relationship (r = 0.52, P < .01).
Figure 6. Tumor histologic differentiations (well-moderated and poorly
differentiated) plotted with respect to the grade of Glut-1 ( G-index)
expressions in AC of lung. The poorly differentiated AC of the lung showed
the highest grade of anti –Glut-1 antibody expression (ANOVA, P < .001). No
staining was observed in specimens from well-differentiated AC. A linear
regression was observed between G-index and the grade of differentiation
(r 2 = 0.45, P < .001).
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appears to be a valuable tool to evaluate small pulmonary
lesions. The PVE leads to underestimation when the struc-
ture is smaller than twice the full width at half-maximum
scanner resolution [34]. Such partial volume effects are par-
ticularly of note when tissue characteristics derived from the
analysis of microscopic specimens are compared to PET
data. However, the specificity in our study (21.4% and
14.3%) was lower than those reported in previous studies
for both analyses (SUV and pSUV, respectively) [15,19,20].
This fact could be attributed to a relatively high incidence of
granulomas in our population and to the selection criteria of
the population (all lesions were surgically resected).
In order to differentiate malignant and nonmalignant
lesions, the uptake of [18F]FDG, translated as SUV, is widely
used in clinical practice. As expected, we observed higher
pSUV values in pulmonary malignant lesions compared to
nonmalignant lesions. The SCCs showed significantly higher
pSUV values than those of nonmalignant lesions and ACs.
However, ACs lesions did not show any significant difference
compared to nonmalignant lesions. Therefore, the differen-
tial diagnosis between ACs and nonmalignant lesions may
be difficult by use of quantitative analysis of [18F]FDG-PET.
Three steps are required for [18F]FDG accumulation in
cancer cells: 1) facilitated diffusion through glucose trans-
port proteins; 2) subsequent phosphorylation by hexokinase
isoforms producing FDG-6-phosphate (FDG-6-P); and 3) de-
creased dephosphorylation. It is believed that the dephos-
phorylation process is negligible and the [18F]FDG-6-P is
neither transported out of cells nor subjected to glycolytic
breakdown; it is metabolically trapped inside cells. Thus,
[18F]FDG accumulation depends basically on the rate of
transport through the cell membrane and the activity of hexo-
kinase [35,36].
Several subtypes of the human facilitative glucose trans-
porters have been described [37]. Glut-1 is the main subtype
that has been shown to overexpress in NSCLC [10–13],
whereas the contribution of the other transporters to the
overall glucose metabolism in NSCLC appears to be minor
[13]. Although several hexokinase subtypes have also been
described, Hexokinase II is suggested to be the main sub-
type in regulating glucose metabolism in cancer cells [14].
Therefore, in the present study, we examined solely the ex-
pression of Glut-1 and HK-II in lung nodules.
In our series, substantial differences in Glut-1 expression
were found in primary lesions of NSCLC of different his-
tology, in which a close correlation between Glut-1 expres-
sion and [18F]FDG uptake was observed in NSCLC. These
results suggest that the overexpression of Glut-1 may have
an important role in the survival of cancer cells by promoting
adequate energy supply in an often-less-than-ideal physio-
logical environment [38,39]. The expression of Glut-1 in SCC
was higher than in AC, which has also been found in previous
studies [11,13]. Based on this higher transport activity in
SCC, we assume that the [18F]FDG uptake in SCCs is higher
than that in AC lesions. The Glut-1 expression in NSCLC
localized preferentially in the edge of the necrotic regions
corresponding to the hypoperfused area. Previous studies
have observed similar findings [11,13].
To our knowledge, this is the first immunohistochemical
study that evaluates HK-II expression and FDG uptake in
NSCLC. The HK-II expression in SCCs showed a higher
level compared to that of ACs. In addition, the present
study also showed a close correlation between the presence
of HK-II and [18F]FDG uptake of NSCLC. Several previous
studies have suggested the possibility that Glut-1 plays a
role of rate-limiting step in the uptake of [18F]FDG in can-
cer cells including primary lung cancer cells [10,11,13]. From
the present study, however, we may conclude that both
Glut-1 and HK-II are important and closely related to
each other.
The degree of cell differentiation correlates with either
Glut-1 or HK-II expressions in AC of the lung. In terms of
Glut-1 expression, a similar result has been reported by Ito
et al. [11]. However, no studies related to HK-II and the
degree of differentiation of AC in lung cancer have been
published. In ACs of the well-differentiated type, both the
low Glut-1 and HK-II expressions seem to be the reason for
the low uptake of [18F]FDG.
To estimate tumor aggressiveness and to determine
patients’ prognoses, the measurement of the proliferation
rate of tumor cells in lung carcinoma is an essential feature.
PCNA, also known as cyclin or auxiliary protein for DNA
polymerase y, is a 36-kDa nuclear polypeptide that is directly
involved in DNA synthesis [40]. Immunohistochemical de-
tection of PCNA has been extensively applied to investi-
gate the proliferation rate of tumor cells in various types of
malignancy [31,41]. In our study population, the [18F]FDG
uptake correlated with proliferative potential measured by
PCNA in NSCLC. Concordant findings have been previously
published [32,42]. We have also observed a good correla-
tion between PCNA expression with either Glut-1 and HK-II
expressions. In tumors with high proliferative potential, glu-
cose metabolism may also increase to produce enough
energy for proliferation.
[18F]FDG is not a tumor-specific tracer. As a result of
increased glycolytic activity, inflammatory cells such as
neutrophils, activated macrophages, and lymphocytes also
Figure 7. A comparative analysis between pSUV values and grade of
inflammatory process in nonmalignant lesions. A linear regression was
observed between pSUV and the grade of inflammation (r 2 = 0.61, P < .05).
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have increased [18F]FDG uptake, producing high [18F]FDG
accumulation at sites of inflammation and infection [22–25].
However, the mechanisms of uptake by these cells are still
not completely understood.
The uptake of [18F]FDG in the whole tumor is considered
to be combined uptake in both neoplastic and non-neoplastic
cellular components [43,44]. Our previous study, using an
animal experimental model, indicates the importance of
cellular immunity employed by T-lymphocytes for [18F]FDG
uptake in tumors [45]. Therefore, in our series, we had ex-
pected that the inflammatory process in the malignant
lesions (expressed as a grade of inflammation) affects FDG
uptake in whole tumor tissues. It seems, however, that the
contribution of inflammatory process to the overall [18F]FDG
uptake in NSCLC is not substantial.
In the present study, we observed a substantial expres-
sion of Glut-1 and HK-II in TB. They were expressed at the
edge of the granulomatous tissue, which has a high accu-
mulation of macrophages. This finding explains the relatively
high [18F]FDG uptake in pulmonary TB. Concerning non-TB
lesions, there was a lack of expression of Glut-1 and HK-II. A
report suggested a possibility that some specific lesions are
more likely to increase the [18F]FDG uptake than others,
depending on the type of inflammatory cells presented at the
infectious/inflammatory sites [46]. However, we have no data
to explain our present results so far. However, we observed a
positive correlation between grading of inflammation and
[18F]FDG uptake in inflammatory lesions, which suggests
that inflammatory cells can take in [18F]FDG, not using solely
the expression of Glut-1 or HK-II, but using the expression of
some other glucose transporters or hexokinases, or others.
Further examination is needed.
One of the limitations of the present study was the relative
lack of precision in ROI positioning of pulmonary lesions with
low FDG uptake. We used the corresponding CT images to
give the best position, although misregistration may occur in
such cases. Improvements would be made by the introduc-
tion of PET/computed tomography (CT) technology. PET/CT
has been shown to be more accurate in characterizing pul-
monary lesions, especially lymphadenopathy [47]. Utility of
PET/CT may make it possible to have a similar comparative
study between FDG uptake and immunoreactivity even in
small lymph nodes in the mediastinum. Another weak point
in the present study was the grading system of inflammation
applied. A well-experienced pathologist in lung disease
(M.K.) defined the inflammatory process based on clinical
experience, and reviewed the specimen twice. There was
no difference in the results between these two trials, which
implied the stability of the grading. However, interobserver
variances were not evaluated in the present study.
Despite the original promise of [18F]FDG PET imaging
for pulmonary disease—that it would allow noninvasive
discrimination between benign and malignant lesions—we
have noted that it was not completely fulfilled. With the future
development of new compounds that are less influenced
by inflammatory processes, there will be an increase in the
specificity of PET studies [47]. Recently, Van Waarde et al.
[23] suggested in their rodent model the possible usefulness
of 18F FLT in the differentiation between malignancies and
benign lesions, compared to FDG. Further evaluation is
needed in human specimens.
Conclusions
Our study indicates that the uptake of [18F]FDG in lung
cancer correlates well with Glut-1, HK-II, and PCNA expres-
sions. As for nonmalignant pulmonary lesions, the presence
of a higher inflammatory process correlated with the uptake
of [18F]FDG. These findings suggest that severe inflamma-
tory process may affect [18F]FDG uptake; therefore, dif-
ferential diagnosis between malignant and nonmalignant
lesions of the lungs should be performed carefully.
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